Last reviewed · How we verify
NCT06819501
Hyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
NA trial testing hyperbaric oxygenation treatment in Breast Cancers in 226 participants. Not yet recruiting.
1 September 2026
Quick facts
| Lead sponsor | Guangdong Provincial People's Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 226 |
| Start date | 5 February 2025 |
| Primary completion | 1 September 2026 |
| Estimated completion | 1 September 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- hyperbaric oxygenation treatment
- routine care
Conditions studied
- Breast Cancers — all drugs for Breast Cancers →
Sponsor
Guangdong Provincial People's Hospital
Who can join
Adults 18 to 60, female only, with Breast Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study was to explore the safety and efficacy of hyperbaric oxygen in the treatment of peripheral neuropathy due to paclitaxel analogues
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06819501
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancers
Currently open trials in the same condition.
- NCT06954623 — Partial Breast Re-irradiation for Breast Cancer · NA · recruiting
- NCT07095023 — Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer · NA · recruiting
- NCT06606730 — Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer · Phase 3 · recruiting
- NCT06960291 — Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada · NA · recruiting
- NCT06811870 — A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatmen · Phase 1, PHASE2 · recruiting
Other Guangdong Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07514611 — Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial · NA · recruiting
- NCT07352930 — A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Can · NA · not yet recruiting
- NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting
- NCT07483398 — RELIEF-PD: Crisugabalin for Nociplastic Pain in Parkinson's Disease · Phase 4 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06819501 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong Provincial People's Hospital
- Last refreshed: 11 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06819501.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing